

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Australian Clinical Labs Limited ( <b>ACL</b> )
<b>ABN</b>	94 645 711 128

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Melinda McGrath
<b>Date of last notice</b>	28 April 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	A.C.N. 633 176 100 Pty Ltd (ACN 633 176 100) as trustee for the McGrath Family Trust is the registered holder of ordinary shares in ACL. Melinda McGrath is a director of A.C.N. 633 176 100 Pty Ltd and is a beneficiary of the McGrath Family Trust.
<b>Date of change</b>	15 September 2022
<b>No. of securities held prior to change</b>	2,857,673 ordinary shares, comprising of 2,173,867 ordinary shares held directly and 683,806 ordinary shares held indirectly.  247,252 Performance rights ( <b>Rights</b> ) issued in accordance with the ACL long-term variable remuneration plan ( <b>LTVR Plan</b> ) in respect of the financial year ending 30 June 2022. The Rights will only vest in accordance with the provisions of the LTVR Plan.
<b>Class</b>	Ordinary
<b>Number acquired</b>	65,658 indirectly
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	DRP price of \$4.27 per ordinary share
<b>No. of securities held after change</b>	2,923,331 ordinary shares, comprising of 2,173,867 ordinary shares held directly and 749,464 ordinary shares held indirectly.  247,252 Performance rights ( <b>Rights</b> ) issued in accordance with the ACL long-term variable remuneration plan ( <b>LTVR Plan</b> ) in respect of the financial year ending 30 June 2022. The Rights will only vest in accordance with the provisions of the LTVR Plan.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares acquired on market and allotted under ACL's dividend reinvestment plan in respect of its interim dividend for FY22.

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<sup>+</sup> See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.